Epiloid Biotechnology
Epiloid Biotechnology specializes in neuropharmaceutical assessment using human brain organoids. Their mission is to transform neurological drug development by providing preclinical efficacy data through innovative organoid models and analysis platforms. They aim to de-risk neurological drug development and advance understanding of brain diseases.
Industries
Nr. of Employees
small (1-50)
Epiloid Biotechnology
Products
Cerebral organoid
Organoid produced via unguided differentiation containing forebrain, midbrain, and hindbrain structures; intended to model broad brain region interactions and diseases such as Machado-Joseph disease.
Forebrain organoid
Guided-differentiation organoid enriched for forebrain-related structures and cell types (oligodendrocytes, microglia, astrocytes, basal radial glia); used to model Fragile X syndrome and Alzheimer's disease.
Midbrain organoid
Guided-differentiation organoid representing midbrain structures (tectum, tegmentum, cerebral peduncles) and cell types including dopaminergic, GABAergic, and glutamatergic neurons; listed disease application: Parkinson's disease.
Hindbrain organoid
Guided-differentiation organoid modeling hindbrain regions (pons, cerebellum, medulla) and cell types such as Purkinje and granule cells.
Cerebral organoid
Organoid produced via unguided differentiation containing forebrain, midbrain, and hindbrain structures; intended to model broad brain region interactions and diseases such as Machado-Joseph disease.
Forebrain organoid
Guided-differentiation organoid enriched for forebrain-related structures and cell types (oligodendrocytes, microglia, astrocytes, basal radial glia); used to model Fragile X syndrome and Alzheimer's disease.
Midbrain organoid
Guided-differentiation organoid representing midbrain structures (tectum, tegmentum, cerebral peduncles) and cell types including dopaminergic, GABAergic, and glutamatergic neurons; listed disease application: Parkinson's disease.
Hindbrain organoid
Guided-differentiation organoid modeling hindbrain regions (pons, cerebellum, medulla) and cell types such as Purkinje and granule cells.
Services
Platform combining human brain organoids and disease models to evaluate neurological drug efficacy at the preclinical stage; documentation states ability to detect molecules affecting epilepsy with a reported 93% precision.
Automated analysis of organoid electrophysiological recordings including phase-amplitude cross-frequency coupling to quantify functional disease signatures and drug effects.
Assays to assess potential adverse effects of compounds on neuronal viability and function using organoid models.
Assessment of cellular energy metabolism and mitochondrial health via extracellular flux-based assays to evaluate compound effects on bioenergetics.
Laboratory services including immunohistochemistry, Western blotting, mass spectrometry, and RNA sequencing for molecular characterization of organoids and other samples.
Provision and use of two-dimensional cell culture systems as complementary in vitro models alongside organoids for comparative assays.
Platform combining human brain organoids and disease models to evaluate neurological drug efficacy at the preclinical stage; documentation states ability to detect molecules affecting epilepsy with a reported 93% precision.
Automated analysis of organoid electrophysiological recordings including phase-amplitude cross-frequency coupling to quantify functional disease signatures and drug effects.
Assays to assess potential adverse effects of compounds on neuronal viability and function using organoid models.
Assessment of cellular energy metabolism and mitochondrial health via extracellular flux-based assays to evaluate compound effects on bioenergetics.
Laboratory services including immunohistochemistry, Western blotting, mass spectrometry, and RNA sequencing for molecular characterization of organoids and other samples.
Provision and use of two-dimensional cell culture systems as complementary in vitro models alongside organoids for comparative assays.
Expertise Areas
- Organoid culture and differentiation
- Disease modeling for neurological disorders
- Preclinical drug efficacy prediction
- Electrophysiological analysis and biomarker extraction
Key Technologies
- Human brain organoids
- Guided and unguided organoid differentiation
- Organoid disease models (epilepsy, Parkinson's, Alzheimer's, Fragile X, Machado-Joseph)
- Electrophysiology and phase-amplitude cross-frequency coupling analysis
News & Updates
Epiloid predicts preclinical drug efficacy through analysis of human brain organoids, aiding in de-risking neurological drug development.
Models have successfully detected molecules with 93% precision influencing epilepsy.
Epiloid predicts preclinical drug efficacy through analysis of human brain organoids, aiding in de-risking neurological drug development.
Models have successfully detected molecules with 93% precision influencing epilepsy.